Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Pharmosa Biopharm's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6875 vs VRTX, REGN, RVMD: OCF Margin % Comparison
For the Biotechnology subindustry, Pharmosa Biopharm's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmosa Biopharm OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmosa Biopharm's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Pharmosa Biopharm's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmosa Biopharm (ROCO:6875) has a OCF Margin % of 0.00% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Pharmosa Biopharm and its competitors. According to the industry distribution chart, Pharmosa Biopharm ranks #720 out of 959 companies in the Biotechnology industry, placing it in the top 75.1%.
Is Pharmosa Biopharm's OCF Margin % too high?
Pharmosa Biopharm's current OCF Margin % is 0.00%. Based on the distribution chart, Pharmosa Biopharm ranks #720 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharmosa Biopharm has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmosa Biopharm's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmosa Biopharm ranks #720 out of 959 companies for OCF Margin %. This places Pharmosa Biopharm in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Pharmosa Biopharm and its competitors. Pharmosa Biopharm's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmosa Biopharm stock overvalued right now?
Based on GuruFocus' analysis, Pharmosa Biopharm (ROCO:6875) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$15.32, compared to a current price of NT$33.00 — trading 115.4% above its estimated fair value. The current OCF Margin % is 0.00%. Pharmosa Biopharm's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Pharmosa Biopharm (ROCO:6875), the current OCF Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmosa Biopharm (ROCO:6875) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmosa Biopharm stock appears to be overvalued.
The current stock price of NT$33.00 is trading 115.4% above its estimated GF Value™ of NT$15.32.
GuruFocus considers Pharmosa Biopharm to be Significantly Overvalued.
Key valuation signals for ROCO:6875:
OCF Margin %: 0.00%
GF Value™: NT$15.32 vs. price of NT$33.00 (115.4% above fair value)
No single metric tells the full story. See the ROCO:6875 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmosa Biopharm Inc is a world-class biotechnology company. The Company's principal business activities comprise the development and commercialization of inventive biopharmaceutical drugs. Its product portfolio includes sustained-release dosage forms and drug-device combination products intended for home based therapies.
27GF Score
Get the complete analysis for ROCO:6875
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6875 has been successfully added to your 
